Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target of $100
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight rating and announces Price Target of $100.
Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight rating and announces Price Target of $100.